Skip to main content

Table 3 Joint effect survival analysis of ODAD2- rs7893462 (GG vs. AA + AG) and clinical parameters in Guangxi HBV-related HCC OS

From: Outer dynein arm docking complex subunit 2 polymorphism rs7893462 modulates hepatocellular carcinoma susceptibility and can serve as an overall survival biomarker for hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a cohort study with a long-term follow-up

Groups

Variables

Genotype

Patients(n = 468)

MST(months)

Crude HR (95% CI)

Crude P

Adjusted HR (95% CI)

Adjusted P

 

Radical resectiona

rs7893462

      

A1

Yes

GG

89

81

1

 

1

 

B2

No

GG

55

93

1.047 (0.619–1.773)

0.863

0.599 (0.327–1.094)

0.095

C3

Yes

AA + AG

172

61

1.318 (0.883–1.976)

0.177

1.277 (0.831–1.963)

0.265

D4

No

AA + AG

143

38

1.843 (1.238–2.744)

0.003

1.344 (0.858–2.108)

0.197

 

Tumor size

       

11

 ≤ 5 cm

GG

62

123

1

 

1

 

22

 > 5 cm

GG

82

78

2.093 (1.199–3.654)

0.009

1.619 (0.870–3.013)

0.128

33

 ≤ 5 cm

AA + AG

127

88

1.370 (0.788–2.382)

0.265

1.395 (0.764–2.549)

0.279

44

 > 5 cm

AA + AG

197

36

3.032 (1.845–4.984)

 < 0.0001

2.861 (1.650–4.959)

0.0002

 

Tumor number

       

Aa

Single

GG

109

96

1

 

1

 

Bb

Multiple

GG

35

75

1.221 (0.693–2.151)

0.489

0.992 (0.508–1.934)

0.98

Cc

Single

AA + AG

237

52

1.350 (0.942–1.937)

0.102

1.487 (1.003–2.205)

0.048

Dd

Multiple

AA + AG

87

28

2.253 (1.495–3.395)

0.0001

2.014 (1.164–3.485)

0.012

 

BCLC

       

A11

A

GG

90

101

1

 

1

 

B22

B

GG

22

75

1.435 (0.698–2.951)

0.326

1.209 (0.512–2.855)

0.665

C33

C

GG

32

34

2.614 (1.461–4.676)

0.001

1.710 (0.765–3.820)

0.191

D44

A

AA + AG

187

88

1.241 (0.802–1.921)

0.332

1.367 (0.846–2.209)

0.201

E55

B

AA + AG

52

39

2.388 (1.430–3.989)

0.001

1.829 (0.901–3.711)

0.095

F66

C

AA + AG

85

18

4.584 (2.935–7.161)

 < 0.0001

3.691 (1.820–7.484)

0.0003

 

Portal vein tumor thrombusb

       

AA1

No

GG

123

93

1

 

1

 

BB2

Yes

GG

21

28

2.569 (1.382–4.775)

0.003

1.038 (0.471–2.288)

0.926

CC3

No

AA + AG

260

71

1.336 (0.944–1.891)

0.102

1.474 (1.011–2.149)

0.043

DD4

Yes

AA + AG

63

14

4.886 (3.239–7.371)

 < 0.0001

2.315 (1.239–4.327)

0.009

 

Serum AFPc

       

AAA

AFP ≤ 400 (ng/mL)

GG

75

81

1

 

1

 

BBB

AFP > 400 (ng/mL)

GG

57

80

1.318 (0.756–2.296)

0.33

0.976 (0.555–1.716)

0.933

CCC

AFP ≤ 400 (ng/mL)

AA + AG

166

57

1.351 (0.975–2.405)

0.064

1.491 (0.944–2.353)

0.087

DDD

AFP > 400 (ng/mL)

AA + AG

136

38

2.080 (1.318–3.284)

0.002

1.783 (1.123–2.832)

0.014

  1. Abbreviation: HBV hepatitis B virus, HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, MST median survival time, OS overall survival, BCLC Barcelona Clinic Liver Cancer, AFP α-fetoprotein, NA not available, ODAD2 outer dynein arm docking complex subunit 2
  2. aInformation of radical resection was unavailable in 9 patients
  3. bInformation of PVTT was unavailable in 1 patient
  4. cInformation of AFP was unavailable in 34 patients
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us